An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice.
Sci Transl Med
; 14(629): eabj5305, 2022 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2325160
ABSTRACT
Global deployment of vaccines that can provide protection across several age groups is still urgently needed to end the COVID-19 pandemic, especially in low- and middle-income countries. Although vaccines against SARS-CoV-2 based on mRNA and adenoviral vector technologies have been rapidly developed, additional practical and scalable SARS-CoV-2 vaccines are required to meet global demand. Protein subunit vaccines formulated with appropriate adjuvants represent an approach to address this urgent need. The receptor binding domain (RBD) is a key target of SARS-CoV-2 neutralizing antibodies but is poorly immunogenic. We therefore compared pattern recognition receptor (PRR) agonists alone or formulated with aluminum hydroxide (AH) and benchmarked them against AS01B and AS03-like emulsion-based adjuvants for their potential to enhance RBD immunogenicity in young and aged mice. We found that an AH and CpG adjuvant formulation (AHCpG) produced an 80-fold increase in anti-RBD neutralizing antibody titers in both age groups relative to AH alone and protected aged mice from the SARS-CoV-2 challenge. The AHCpG-adjuvanted RBD vaccine elicited neutralizing antibodies against both wild-type SARS-CoV-2 and the B.1.351 (beta) variant at serum concentrations comparable to those induced by the licensed Pfizer-BioNTech BNT162b2 mRNA vaccine. AHCpG induced similar cytokine and chemokine gene enrichment patterns in the draining lymph nodes of both young adult and aged mice and enhanced cytokine and chemokine production in human mononuclear cells of younger and older adults. These data support further development of AHCpG-adjuvanted RBD as an affordable vaccine that may be effective across multiple age groups.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Hidróxido de Aluminio
/
COVID-19
Tipo de estudio:
Estudio experimental
/
Ensayo controlado aleatorizado
Tópicos:
Vacunas
/
Variantes
Límite:
Anciano
/
Animales
/
Humanos
Idioma:
Inglés
Revista:
Sci Transl Med
Asunto de la revista:
Ciencia
/
Medicina
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
Scitranslmed.abj5305
Similares
MEDLINE
...
LILACS
LIS